ES2444574T3 - N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa - Google Patents
N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa Download PDFInfo
- Publication number
- ES2444574T3 ES2444574T3 ES07814905.1T ES07814905T ES2444574T3 ES 2444574 T3 ES2444574 T3 ES 2444574T3 ES 07814905 T ES07814905 T ES 07814905T ES 2444574 T3 ES2444574 T3 ES 2444574T3
- Authority
- ES
- Spain
- Prior art keywords
- alkyl
- nrc5rd5
- alkynyl
- alkenyl
- haloalkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/12—Ophthalmic agents for cataracts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/20—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings condensed with carbocyclic rings or ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/56—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Oncology (AREA)
- Virology (AREA)
- Pulmonology (AREA)
- Psychiatry (AREA)
- Communicable Diseases (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
- Pain & Pain Management (AREA)
- Hematology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Molecular Biology (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US84570006P | 2006-09-19 | 2006-09-19 | |
| US845700P | 2006-09-19 | ||
| PCT/US2007/078745 WO2008036642A2 (en) | 2006-09-19 | 2007-09-18 | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ES2444574T3 true ES2444574T3 (es) | 2014-02-25 |
Family
ID=38969441
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ES07814905.1T Active ES2444574T3 (es) | 2006-09-19 | 2007-09-18 | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20080125470A1 (cg-RX-API-DMAC10.html) |
| EP (1) | EP2064207B1 (cg-RX-API-DMAC10.html) |
| JP (1) | JP5319532B2 (cg-RX-API-DMAC10.html) |
| CA (1) | CA2663057C (cg-RX-API-DMAC10.html) |
| ES (1) | ES2444574T3 (cg-RX-API-DMAC10.html) |
| WO (1) | WO2008036642A2 (cg-RX-API-DMAC10.html) |
Families Citing this family (159)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BRPI0307077A2 (pt) * | 2002-01-22 | 2017-06-20 | Biomatera Inc | método para secar polímeros biodegradáveis |
| DE602006001511D1 (de) * | 2005-02-04 | 2008-07-31 | Ctg Pharma S R L | Neue 4-aminochinolinderivate als antimalariamittel |
| RS54876B1 (sr) | 2005-05-10 | 2016-10-31 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| ES2540561T3 (es) | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080182882A1 (en) * | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| DK2315756T5 (en) | 2008-07-08 | 2015-08-03 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase |
| HK1209742A1 (en) | 2012-11-20 | 2016-04-08 | 沃泰克斯药物股份有限公司 | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase |
| EP3492094A1 (en) | 2013-08-30 | 2019-06-05 | Board of Regents, The University of Texas System | Administration of kynurenine depleting enzymes for tumor therapy |
| TWI651311B (zh) | 2013-11-08 | 2019-02-21 | 英塞特控股公司 | 用於合成吲哚胺２，３－雙加氧酶抑制劑之方法 |
| LT3087071T (lt) | 2013-12-24 | 2018-11-12 | Bristol-Myers Squibb Company | Tricikliniai junginiai kaip priešvėžiniai agentai |
| RS59643B1 (sr) | 2014-06-06 | 2020-01-31 | Bristol Myers Squibb Co | Antitela na glukokortikoidom indukovani receptor faktora nekroze tumora (gitr) i njihova primena |
| JP7080053B2 (ja) | 2014-08-29 | 2022-06-03 | ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム | 腫瘍の治療のための、キヌレニンを枯渇させる酵素の投与 |
| WO2016081748A2 (en) | 2014-11-21 | 2016-05-26 | Bristol-Myers Squibb Company | Antibodies against cd73 and uses thereof |
| TW201630907A (zh) | 2014-12-22 | 2016-09-01 | 必治妥美雅史谷比公司 | ＴＧＦβＲ拮抗劑 |
| SG10202006538TA (en) | 2014-12-23 | 2020-08-28 | Bristol Myers Squibb Co | Antibodies to tigit |
| WO2016127052A1 (en) | 2015-02-05 | 2016-08-11 | Bristol-Myers Squibb Company | Cxcl11 and smica as predictive biomarkers for efficacy of anti-ctla4 immunotherapy |
| WO2016140884A1 (en) | 2015-03-02 | 2016-09-09 | Rigel Pharmaceuticals, Inc. | TGF-β INHIBITORS |
| US10399933B2 (en) | 2015-04-03 | 2019-09-03 | Bristol-Myers Squibb Company | Inhibitors of indoleamine-2,3-dioxygenase for the treatment of cancer |
| TW201642897A (zh) | 2015-04-08 | 2016-12-16 | Ｆ 星生物科技有限公司 | Ｈｅｒ２結合劑治療 |
| CN107709365A (zh) | 2015-04-13 | 2018-02-16 | 戊瑞治疗有限公司 | 癌症组合疗法 |
| US10683290B2 (en) | 2015-05-11 | 2020-06-16 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| EP3307740B1 (en) | 2015-05-12 | 2019-12-18 | Bristol-Myers Squibb Company | 5h-pyrido[3,2-b]indole compounds as anticancer agents |
| US9725449B2 (en) | 2015-05-12 | 2017-08-08 | Bristol-Myers Squibb Company | Tricyclic compounds as anticancer agents |
| PT3303396T (pt) | 2015-05-29 | 2023-01-30 | Bristol Myers Squibb Co | Anticorpos contra ox40 e utilizações dos mesmos |
| UY36757A (es) | 2015-06-29 | 2016-12-30 | Bristol Myers Squibb Company Una Corporación Del Estado De Delaware | Anticuerpos monoclonales murinos contra cd40 con actividad agonista mejorada |
| EP3328861A1 (en) | 2015-07-28 | 2018-06-06 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| WO2017035118A1 (en) | 2015-08-25 | 2017-03-02 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| MX2018005517A (es) | 2015-11-02 | 2018-11-09 | Five Prime Therapeutics Inc | Polipeptidos del dominio extracelular de cd80 y su uso en el tratamiento del cancer. |
| EA201891121A1 (ru) | 2015-11-19 | 2018-12-28 | Бристол-Майерс Сквибб Компани | Антитела к глюкокортикоид-индуцированному рецептору фактора некроза опухоли (gitr) и их применения |
| TWI791422B (zh) | 2015-11-23 | 2023-02-11 | 美商戊瑞治療有限公司 | 用於癌症治療之單獨fgfr2抑制劑或與免疫刺激劑組合 |
| EP3390406A1 (en) | 2015-12-15 | 2018-10-24 | Bristol-Myers Squibb Company | Cxcr4 receptor antagonists |
| EP3416725A1 (en) | 2016-02-19 | 2018-12-26 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods and pharmaceutical compositions for the treatment of obesity |
| WO2017151860A1 (en) | 2016-03-02 | 2017-09-08 | Broard Of Regents, The University Of Texas System | Human kynureninase enzyme variants having improved pharmacological properties |
| SG11201806861SA (en) | 2016-03-04 | 2018-09-27 | Bristol Myers Squibb Co | Combination therapy with anti-cd73 antibodies |
| WO2017184619A2 (en) | 2016-04-18 | 2017-10-26 | Celldex Therapeutics, Inc. | Agonistic antibodies that bind human cd40 and uses thereof |
| KR20190004742A (ko) | 2016-05-04 | 2019-01-14 | 브리스톨-마이어스 스큅 컴퍼니 | 인돌아민 2,3-디옥시게나제의 억제제 및 그의 사용 방법 |
| US10696648B2 (en) | 2016-05-04 | 2020-06-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| CN109414421A (zh) | 2016-05-04 | 2019-03-01 | 百时美施贵宝公司 | 吲哚胺2,3-双加氧酶的抑制剂及其使用方法 |
| US10323004B2 (en) | 2016-05-04 | 2019-06-18 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| JP2019519485A (ja) | 2016-05-04 | 2019-07-11 | ブリストル−マイヤーズ スクイブ カンパニーＢｒｉｓｔｏｌ−Ｍｙｅｒｓ Ｓｑｕｉｂｂ Ｃｏｍｐａｎｙ | インドールアミン２，３−ジオキシゲナーゼ阻害剤およびその使用方法 |
| WO2018013818A2 (en) | 2016-07-14 | 2018-01-18 | Bristol-Myers Squibb Company | Antibodies against tim3 and uses thereof |
| US20190292179A1 (en) | 2016-07-21 | 2019-09-26 | Bristol-Myers Squibb Company | TGF Beta RECEPTOR ANTAGONISTS |
| WO2018039518A1 (en) | 2016-08-26 | 2018-03-01 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| UY37466A (es) | 2016-11-03 | 2018-01-31 | Phenex Discovery Verwaltungs Gmbh | N-hidroxiamidinheterociclos sustituidos como moduladores de la indolamina 2,3-dioxigenasa |
| HUE054272T2 (hu) | 2016-12-22 | 2021-09-28 | Calithera Biosciences Inc | Összetételek és módszerek az argináz-tevékenység gátlásához |
| WO2018132279A1 (en) | 2017-01-05 | 2018-07-19 | Bristol-Myers Squibb Company | Tgf beta receptor antagonists |
| WO2018136437A2 (en) | 2017-01-17 | 2018-07-26 | Tesaro, Inc. | Compounds useful as inhibitors of indoleamine 2,3-dioxygenase and/or tryptophan dioxygenase |
| CA3057312A1 (en) * | 2017-03-29 | 2018-10-04 | Merck Sharp & Dohme Corp. | Novel substituted n'-hydroxycarbamimidoyl-1,2,5-oxadiazole compounds as indoleamine 2,3-dioxygenase (ido) inhibitors |
| EP3601353A1 (en) | 2017-03-31 | 2020-02-05 | Five Prime Therapeutics, Inc. | Combination therapy for cancer using anti-gitr antibodies |
| TWI788340B (zh) | 2017-04-07 | 2023-01-01 | 美商必治妥美雅史谷比公司 | 抗icos促效劑抗體及其用途 |
| EP3612030B1 (en) | 2017-04-21 | 2025-12-24 | Ikena Oncology, Inc. | Indole ahr inhibitors and uses thereof |
| MX2019012849A (es) | 2017-04-28 | 2019-11-28 | Five Prime Therapeutics Inc | Metodos de tratamiento con polipeptidos del dominio extracelular del cd80. |
| WO2018209049A1 (en) | 2017-05-12 | 2018-11-15 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| KR101965348B1 (ko) * | 2017-06-26 | 2019-04-03 | 한국화학연구원 | N'-히드록시인다졸카르복시이미다미드 유도체 화합물, 이의 광학이성질체, 또는 이의 약학적으로 허용가능한 염, 및, 이를 유효성분으로 포함하는 항암용 조성물 |
| WO2019003141A1 (en) * | 2017-06-28 | 2019-01-03 | Glaxosmithkline Intellectual Property Development Limited | MODULATORS OF INDOLAMINE 2,3-DIOXYGENASE |
| CA3066969A1 (en) * | 2017-06-28 | 2019-01-03 | Glaxosmithkline Intellectual Property Development Limited | Modulators of indoleamine 2,3-dioxygenase |
| CN111093651B (zh) | 2017-06-30 | 2023-06-06 | 百时美施贵宝公司 | Ido抑制剂的无定形和结晶形式 |
| JP7186764B2 (ja) | 2017-07-28 | 2022-12-09 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| EP3668496A4 (en) | 2017-08-17 | 2021-07-14 | Ikena Oncology, Inc. | AHR INHIBITORS AND THEIR USES |
| CN111032672B (zh) | 2017-08-31 | 2024-09-13 | 百时美施贵宝公司 | 作为抗癌剂的环二核苷酸 |
| ES2904317T3 (es) | 2017-08-31 | 2022-04-04 | Bristol Myers Squibb Co | Dinucleótidos cíclicos como agentes anticancerosos |
| JP7209697B2 (ja) | 2017-08-31 | 2023-01-20 | ブリストル－マイヤーズ スクイブ カンパニー | 抗癌剤としての環状ジヌクレオチド |
| EP3676263B1 (en) | 2017-09-01 | 2021-10-06 | Netherlands Translational Research Center B.V. | 3-hydroxy-imidazolidin-4-one compounds as inhibitors of indoleamine 2,3-dioxygenase |
| WO2019074824A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| WO2019074822A1 (en) | 2017-10-09 | 2019-04-18 | Bristol-Myers Squibb Company | INDOLEAMINE 2,3-DIOXYGENASE INHIBITORS AND METHODS OF USE |
| EP3694867B1 (en) | 2017-10-10 | 2025-12-24 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| WO2019075090A1 (en) | 2017-10-10 | 2019-04-18 | Tilos Therapeutics, Inc. | ANTI-LAP ANTIBODIES AND USES THEREOF |
| US11427610B2 (en) | 2017-10-16 | 2022-08-30 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| EP3704159A1 (en) | 2017-11-01 | 2020-09-09 | Bristol-Myers Squibb Company | Immunostimulatory agonistic antibodies for use in treating cancer |
| WO2019090198A1 (en) | 2017-11-06 | 2019-05-09 | Bristol-Myers Squibb Company | Isofuranone compounds useful as hpk1 inhibitors |
| EP3724177A1 (en) | 2017-12-12 | 2020-10-21 | Phenex Discovery Verwaltungs-GmbH | Oxalamides as modulators of indoleamine 2,3-dioxygenase |
| JP7284759B2 (ja) | 2017-12-27 | 2023-05-31 | ブリストル－マイヤーズ スクイブ カンパニー | 抗ｃｄ４０抗体およびその使用 |
| US11447449B2 (en) | 2018-01-05 | 2022-09-20 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| JP7358361B2 (ja) | 2018-01-12 | 2023-10-10 | ブリストル－マイヤーズ スクイブ カンパニー | Ｔｉｍ３に対する抗体およびその使用 |
| US10519187B2 (en) | 2018-02-13 | 2019-12-31 | Bristol-Myers Squibb Company | Cyclic dinucleotides as anticancer agents |
| KR20200130362A (ko) | 2018-03-08 | 2020-11-18 | 브리스톨-마이어스 스큅 컴퍼니 | 항암제로서의 시클릭 디뉴클레오티드 |
| WO2019183040A1 (en) | 2018-03-21 | 2019-09-26 | Five Prime Therapeutics, Inc. | ANTIBODIES BINDING TO VISTA AT ACIDIC pH |
| JP7351845B2 (ja) | 2018-03-23 | 2023-09-27 | ブリストル－マイヤーズ スクイブ カンパニー | Ｍｉｃａおよび／またはｍｉｃｂに対する抗体ならびにそれらの使用 |
| WO2019185870A1 (en) | 2018-03-29 | 2019-10-03 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
| EP3773714A1 (en) | 2018-04-12 | 2021-02-17 | Bristol-Myers Squibb Company | Anticancer combination therapy with cd73 antagonist antibody and pd-1/pd-l1 axis antagonist antibody |
| AU2019255196A1 (en) | 2018-04-16 | 2020-11-12 | Arrys Therapeutics, Inc. | EP4 inhibitors and use thereof |
| KR102862473B1 (ko) | 2018-04-16 | 2025-09-23 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 인간 키누레니나제 효소 및 이의 사용법 |
| WO2019206800A1 (en) | 2018-04-24 | 2019-10-31 | Phenex Discovery Verwaltungs-GmbH | Spirocyclic compounds as modulators of indoleamine 2,3-dioxygenase |
| WO2019213340A1 (en) | 2018-05-03 | 2019-11-07 | Bristol-Myers Squibb Company | Uracil derivatives as mer-axl inhibitors |
| FI3814348T3 (fi) | 2018-06-27 | 2023-09-22 | Bristol Myers Squibb Co | Substituoituja naftyridinoniyhdisteitä, jotka ovat käyttökelpoisia t-solun aktivoijina |
| LT3814347T (lt) | 2018-06-27 | 2023-07-10 | Bristol-Myers Squibb Company | Naftiridinono junginiai naudotini kaip t ląstelių aktyvatoriai |
| PE20211604A1 (es) | 2018-07-09 | 2021-08-23 | Five Prime Therapeutics Inc | Anticuerpos de union a ilt4 |
| AU2019301120A1 (en) | 2018-07-11 | 2021-02-25 | Bristol-Myers Squibb Company | Antibodies binding to VISTA at acidic pH |
| EP3823604A4 (en) | 2018-07-17 | 2022-03-16 | Board of Regents, The University of Texas System | COMPOUNDS AS INHIBITORS OF INDOLAMINE-2,3-DIOXYGENASE AND/OR TRYPTOPHANE DIOXYGENASE |
| WO2020023355A1 (en) | 2018-07-23 | 2020-01-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US12145927B2 (en) | 2018-07-23 | 2024-11-19 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US11253525B2 (en) | 2018-08-29 | 2022-02-22 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| US10959986B2 (en) | 2018-08-29 | 2021-03-30 | Bristol-Myers Squibb Company | Inhibitors of indoleamine 2,3-dioxygenase and methods of their use |
| WO2020076969A2 (en) | 2018-10-10 | 2020-04-16 | Tilos Therapeutics, Inc. | Anti-lap antibody variants and uses thereof |
| WO2020102501A1 (en) | 2018-11-16 | 2020-05-22 | Bristol-Myers Squibb Company | Anti-nkg2a antibodies and uses thereof |
| US20230295087A1 (en) | 2019-05-13 | 2023-09-21 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| US12012374B2 (en) | 2019-05-13 | 2024-06-18 | Bristol-Myers Squibb Company | Agonists of ROR GAMMAt |
| WO2021026179A1 (en) | 2019-08-06 | 2021-02-11 | Bristol-Myers Squibb Company | AGONISTS OF ROR GAMMAt |
| AR119821A1 (es) | 2019-08-28 | 2022-01-12 | Bristol Myers Squibb Co | Compuestos de piridopirimidinonilo sustituidos útiles como activadores de células t |
| MX2022003204A (es) | 2019-09-19 | 2022-04-18 | Bristol Myers Squibb Co | Anticuerpos de union al supresor de activacion de linfocitos t que contiene inmunoglobulina con dominio v (vista) a ph acido. |
| US11548870B2 (en) | 2019-11-19 | 2023-01-10 | Bristol-Myers Squibb Company | Compounds useful as inhibitors of helios protein |
| US12527783B2 (en) | 2019-11-26 | 2026-01-20 | Bristol-Myers Squibb Company | Salts/cocrystals of (R)-N-(4-chlorophenyl-2-((1S,4S)-4-(6-fluoroquinolin-4-yl)cyclohexyl)propanamide |
| CA3159317A1 (en) | 2019-11-26 | 2021-06-03 | Alfredo C. Castro | Polymorphic carbazole derivatives and uses thereof |
| CN114846015B (zh) | 2019-12-23 | 2024-07-30 | 百时美施贵宝公司 | 用作t细胞激活剂的经取代的杂芳基化合物 |
| AU2020412698A1 (en) | 2019-12-23 | 2022-08-18 | Bristol-Myers Squibb Company | Substituted piperazine derivatives useful as T cell activators |
| WO2021133748A1 (en) | 2019-12-23 | 2021-07-01 | Bristol-Myers Squibb Company | Substituted quinolinonyl piperazine compounds useful as t cell activators |
| EP4081516B1 (en) | 2019-12-23 | 2025-07-30 | Bristol-Myers Squibb Company | Substituted quinazolinyl compounds useful as t cell activators |
| AR120823A1 (es) | 2019-12-23 | 2022-03-23 | Bristol Myers Squibb Co | Compuestos bicíclicos sustituidos útiles como activadores de células t |
| US20230045791A1 (en) | 2020-01-06 | 2023-02-16 | Hifibio (Hk) Limited | Anti-tnfr2 antibody and uses thereof |
| AU2021205143A1 (en) | 2020-01-07 | 2022-07-28 | Hifibio, Inc. | Anti-Galectin-9 antibody and uses thereof |
| US11534441B2 (en) | 2020-01-15 | 2022-12-27 | Blueprint Medicines Corporation | MAP4K1 inhibitors |
| KR20220151189A (ko) | 2020-03-09 | 2022-11-14 | 브리스톨-마이어스 스큅 컴퍼니 | 증진된 효능제 활성을 갖는 cd40에 대한 항체 |
| TW202140441A (zh) | 2020-03-23 | 2021-11-01 | 美商必治妥美雅史谷比公司 | 經取代之側氧基異吲哚啉化合物 |
| WO2021207449A1 (en) | 2020-04-09 | 2021-10-14 | Merck Sharp & Dohme Corp. | Affinity matured anti-lap antibodies and uses thereof |
| WO2021231732A1 (en) | 2020-05-15 | 2021-11-18 | Bristol-Myers Squibb Company | Antibodies to garp |
| WO2021258010A1 (en) | 2020-06-19 | 2021-12-23 | Gossamer Bio Services, Inc. | Oxime compounds useful as t cell activators |
| CA3188996A1 (en) | 2020-08-10 | 2022-02-17 | Tengfei XIAO | Compositions and methods for treating autoimmune diseases and cancers by targeting igsf8 |
| US20230416382A1 (en) | 2020-10-14 | 2023-12-28 | Five Prime Therapeutics, Inc. | Anti-c-c chemokine receptor 8 (ccr8) antibodies and methods of use thereof |
| CA3202330A1 (en) | 2020-12-16 | 2022-06-23 | Anthony Casarez | Compounds useful as t cell activators |
| US20240109899A1 (en) | 2021-02-04 | 2024-04-04 | Bristol-Myers Squibb Company | Benzofuran compounds as sting agonists |
| EP4291558A1 (en) | 2021-02-12 | 2023-12-20 | F. Hoffmann-La Roche AG | Bicyclic tetrahydroazepine derivatives for the treatment of cancer |
| EP4305041A1 (en) | 2021-03-08 | 2024-01-17 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| US11918582B2 (en) | 2021-03-15 | 2024-03-05 | Rapt Therapeutics, Inc. | Pyrazole pyrimidine compounds and uses thereof |
| JP2024514530A (ja) | 2021-04-02 | 2024-04-02 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | 切断型ｃｄｃｐ１に対する抗体およびその使用 |
| JP2024515545A (ja) | 2021-04-05 | 2024-04-10 | ブリストル－マイヤーズ スクイブ カンパニー | がん治療のためのピリジニル置換オキソイソインドリン化合物 |
| PE20231941A1 (es) | 2021-04-06 | 2023-12-05 | Bristol Myers Squibb Co | Compuestos de oxoisoindolina sustituidos con piridinilo |
| TW202321237A (zh) | 2021-07-14 | 2023-06-01 | 美商纜圖藥品公司 | Ｍａｐ４ｋ１抑制劑 |
| WO2023288264A1 (en) | 2021-07-15 | 2023-01-19 | Blueprint Medicines Corporation | Map4k1 inhibitors |
| WO2023122772A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122777A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Oxime derivatives useful as t cell activators |
| WO2023122778A1 (en) | 2021-12-22 | 2023-06-29 | Gossamer Bio Services, Inc. | Pyridazinone derivatives useful as t cell activators |
| EP4472963A1 (en) | 2022-02-01 | 2024-12-11 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| CN119654312A (zh) | 2022-08-08 | 2025-03-18 | 百时美施贵宝公司 | 用作t细胞活化剂的取代的四唑基化合物 |
| WO2024036101A1 (en) | 2022-08-09 | 2024-02-15 | Bristol-Myers Squibb Company | Tertiary amine substituted bicyclic compounds useful as t cell activators |
| EP4568958A1 (en) | 2022-08-11 | 2025-06-18 | F. Hoffmann-La Roche AG | Bicyclic tetrahydrothiazepine derivatives |
| WO2024033389A1 (en) | 2022-08-11 | 2024-02-15 | F. Hoffmann-La Roche Ag | Bicyclic tetrahydrothiazepine derivatives |
| TW202417001A (zh) | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫吖呯衍生物 |
| TW202417439A (zh) | 2022-08-11 | 2024-05-01 | 瑞士商赫孚孟拉羅股份公司 | 雙環四氫噻吖呯衍生物 |
| WO2024137865A1 (en) | 2022-12-22 | 2024-06-27 | Gossamer Bio Services, Inc. | Compounds useful as t cell activators |
| TW202500139A (zh) | 2023-05-08 | 2025-01-01 | 美商必治妥美雅史谷比公司 | 經取代之苯基㗁唑酮化合物 |
| TW202509014A (zh) | 2023-05-10 | 2025-03-01 | 美商纜圖藥品公司 | ＧＳＫ３α抑制劑及其使用方法 |
| WO2024249540A1 (en) | 2023-05-31 | 2024-12-05 | Bristol-Myers Squibb Company | Substituted oxazolone compound for decreasing levels of ikzf1-4 proteins |
| AU2024285766A1 (en) | 2023-06-07 | 2026-01-08 | Bristol-Myers Squibb Company | Spirocyclic substituted oxoisoindolinyl piperidine-2,6-dione compound |
| WO2024263853A1 (en) | 2023-06-23 | 2024-12-26 | Bristol-Myers Squibb Company | Substituted oxoisoindolinyl piperidine-2,6-dione compound as anticancer agent |
| WO2025030002A2 (en) | 2023-08-02 | 2025-02-06 | Arvinas Operations, Inc. | Dgk targeting compounds and uses thereof |
| WO2025064197A1 (en) | 2023-09-02 | 2025-03-27 | Bristol-Myers Squibb Company | Substituted azetidinyl oxoisoindolinyl piperidine-2,6-dione compounds |
| AR133696A1 (es) | 2023-09-02 | 2025-10-22 | Bristol Myers Squibb Co | Compuestos de fenil oxooxazolil piperidinadiona sustituida |
| JP7808733B2 (ja) | 2023-09-13 | 2026-01-29 | ブリストル－マイヤーズ スクイブ カンパニー | 置換オキソイソインドリニルピペリジン－２，６－ジオン化合物 |
| WO2025096505A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096488A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096489A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096494A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| US20250145590A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096490A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025096487A1 (en) | 2023-10-31 | 2025-05-08 | Bristol-Myers Squibb Company | Ubiquitin specific processing protease 1 (usp1) compounds |
| WO2025226767A1 (en) | 2024-04-24 | 2025-10-30 | Bristol-Myers Squibb Company | Substituted 3-(5-(6-aminopyridin-2-yl)-4-fluoro-1-oxoisoindolin-2-yl)piperidine-2,6-dione compounds for use in the treatment of cancer |
Family Cites Families (65)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3354174A (en) | 1964-02-19 | 1967-11-21 | Sterling Drug Inc | 1-and 2-benzimidazolyl-lower-alkylamidoximes, amidines-, and guanidines |
| US3286855A (en) * | 1965-06-01 | 1966-11-22 | Standard Trailer Company | Crane extension and resulting crane assembly |
| US3553228A (en) * | 1967-09-26 | 1971-01-05 | Colgate Palmolive Co | 3-substituted-4h(1)benzopyrano(3,4-d) isoxazoles |
| DE2040628A1 (de) | 1970-08-17 | 1972-02-24 | Fahlberg List Veb | Neue herbizide Mittel |
| US3948928A (en) * | 1972-03-17 | 1976-04-06 | Dainippon Pharmaceutical Co., Ltd. | 3-Substituted-1,2-benzisoxazoles and pharmaceutically acceptable acid addition salts thereof |
| JPS5621033B2 (cg-RX-API-DMAC10.html) * | 1973-09-05 | 1981-05-16 | ||
| FR2323683A1 (fr) | 1975-09-11 | 1977-04-08 | Philagro Sa | Nouveaux derives d'amidoximes, leur preparation et les compositions qui les contiennent |
| DE2640484A1 (de) * | 1975-09-11 | 1977-04-07 | Philagro Sa | Amidoxim-derivate, ihre herstellung und verwendung |
| US4323681A (en) * | 1980-09-29 | 1982-04-06 | American Home Products Corporation | 4-Amino-2-substituted-5-pyrimidinecarboxamidoximes and carbothioamides |
| JPS58208275A (ja) | 1982-05-20 | 1983-12-03 | Lion Corp | ５−アミノ−ピラゾ−ル誘導体及び該化合物を含有する抗腫瘍剤 |
| DE3462259D1 (de) * | 1983-07-22 | 1987-03-05 | Bayer Ag | Substituted furazans |
| JPS60193968A (ja) | 1984-03-13 | 1985-10-02 | Toyo Jozo Co Ltd | シクロペンテン環を有するイミダゾ−ルアミドオキシムおよびその製造法 |
| JPS6259283A (ja) | 1985-09-10 | 1987-03-14 | Kaken Pharmaceut Co Ltd | セフアロスポリン化合物 |
| JP2696342B2 (ja) | 1988-06-27 | 1998-01-14 | 日本曹達株式会社 | アミジン誘導体、その製造方法及び殺ダニ剤・農園芸用殺菌剤 |
| DE68901424D1 (de) | 1988-07-05 | 1992-06-11 | Akzo Nv | Verbindungen mit bronchodilatatorischer aktivitaet. |
| JPH04297449A (ja) | 1991-03-27 | 1992-10-21 | Hokko Chem Ind Co Ltd | Ｎ−ヒドロキシベンジルグアニジン誘導体および農園芸用殺菌剤 |
| JPH05186458A (ja) | 1991-04-26 | 1993-07-27 | Japan Tobacco Inc | 新規なベンゾピラン誘導体 |
| FR2677019B1 (fr) * | 1991-05-27 | 1994-11-25 | Pf Medicament | Nouvelles piperidines disubstituees-1,4, leur preparation et leur application en therapeutique. |
| JP2709677B2 (ja) | 1992-06-19 | 1998-02-04 | 株式会社大塚製薬工場 | ホスホン酸ジエステル誘導体 |
| FR2720396B1 (fr) * | 1994-05-27 | 1996-06-28 | Adir | Nouveaux N-pyridyl carboxamides et dérivés leur procédé de préparation et les compositions pharmaceutiques qui les contiennent. |
| US5731315A (en) | 1995-06-07 | 1998-03-24 | Rhone-Poulenc Rorer Pharmaceuticals Inc. | Substituted sulfonic acid n- (aminoiminomethyl)phenylalkyl!-azaheterocyclamide compounds |
| NZ319673A (en) | 1995-10-17 | 2000-06-23 | Astra Pharma Prod | Quinazoline compounds for inflammatory disorders such rheumatoid arthritis or osteoarthritis |
| WO1997030047A1 (en) | 1996-02-17 | 1997-08-21 | Agrevo Uk Limited | Fungicidal 1,2,4-oxadiazoles and analogues |
| US5955495A (en) | 1996-05-03 | 1999-09-21 | Hoffmann-La Roche Inc. | Method of treating diseases of the CNS |
| JPH11171702A (ja) | 1997-09-24 | 1999-06-29 | Takeda Chem Ind Ltd | 害虫防除方法 |
| AU1628599A (en) | 1997-12-05 | 1999-06-28 | Medical College Of Georgia Research Institute, Inc. | Regulation of t cell-mediated immunity by tryptophan |
| US6340697B1 (en) | 1997-12-10 | 2002-01-22 | Dainippon Ink And Chemicals, Inc. | Oxime derivatives and agricultural chemicals containing the same |
| US6288088B1 (en) | 1998-06-02 | 2001-09-11 | Takeda Chemical Industries, Ltd. | Oxadiazoline derivative and their use as insecticides |
| FR2784678B1 (fr) * | 1998-09-23 | 2002-11-29 | Sod Conseils Rech Applic | Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant |
| JP3422486B2 (ja) | 1999-03-03 | 2003-06-30 | サムジン ファーマシューティカル カンパニー リミテッド | ピペラジン誘導体及びその製造方法 |
| IL145772A0 (en) | 1999-04-09 | 2002-07-25 | Basf Ag | Prodrugs of thrombin inhibitors |
| EA004704B1 (ru) | 1999-05-24 | 2004-06-24 | Мицубиси Фарма Корпорейшн | Производные феноксипропиламина |
| JP2001158785A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 農薬組成物 |
| JP2001158786A (ja) | 1999-11-30 | 2001-06-12 | Takeda Chem Ind Ltd | 哺乳動物の外部寄生虫防除剤 |
| DE60131138T2 (de) | 2000-01-13 | 2008-08-14 | Amgen Inc., Thousand Oaks | Antibakterielle mittel |
| NZ522783A (en) | 2000-06-28 | 2004-07-30 | Smithkline Beecham P | Wet milling process for pharmaceuticals with agitator or chamber having nylon with internal lubricant |
| GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| AU2002319237B2 (en) * | 2001-06-18 | 2008-01-03 | Merck Serono Sa | Pyrrolidine oxadiazole- and thiadiazole oxime derivatives being oxytocin receptor antagonists |
| GB0208224D0 (en) | 2002-04-10 | 2002-05-22 | Celltech R&D Ltd | Chemical compounds |
| US20030194803A1 (en) | 2002-04-12 | 2003-10-16 | Mellor Andrew L. | Antigen-presenting cell populations and their use as reagents for enhancing or reducing immune tolerance |
| TW200406395A (en) | 2002-05-28 | 2004-05-01 | Dimensional Pharm Inc | Novel thiophene amidines, compositions thereof, and methods of treating complement-mediated diseases and conditions |
| US7157462B2 (en) | 2002-09-24 | 2007-01-02 | Euro-Celtique S.A. | Therapeutic agents useful for treating pain |
| EP1613308A4 (en) | 2003-03-27 | 2008-02-20 | Lankenau Inst Medical Res | CANCER TREATMENT METHODS |
| US7598287B2 (en) * | 2003-04-01 | 2009-10-06 | Medical College Of Georgia Research Institute, Inc. | Use of inhibitors of indoleamine-2,3-dioxygenase in combination with other therapeutic modalities |
| EP1660467B1 (en) | 2003-08-20 | 2011-12-07 | Vertex Pharmaceuticals Incorporated | 2-(4-amino-1,2,5-oxadiazol-4-yl)-imidazole compounds useful as protein kinase inhibitors |
| DE10348022A1 (de) | 2003-10-15 | 2005-05-25 | Imtm Gmbh | Neue Dipeptidylpeptidase IV-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| DE10348023A1 (de) | 2003-10-15 | 2005-05-19 | Imtm Gmbh | Neue Alanyl-Aminopeptidasen-Inhibitoren zur funktionellen Beeinflussung unterschiedlicher Zellen und zur Behandlung immunologischer, entzündlicher, neuronaler und anderer Erkrankungen |
| TW200619212A (en) * | 2004-09-08 | 2006-06-16 | Mitsubishi Pharma Corp | Morpholine derivatives |
| WO2006067532A1 (en) | 2004-12-24 | 2006-06-29 | Prosidion Ltd | G-protein coupled receptor agonists |
| US7429667B2 (en) * | 2005-01-20 | 2008-09-30 | Ardea Biosciences, Inc. | Phenylamino isothiazole carboxamidines as MEK inhibitors |
| RS54876B1 (sr) | 2005-05-10 | 2016-10-31 | Incyte Holdings Corp | Modulatori indoleamina 2,3-dioksigenaze i metode za upotrebu istih |
| WO2006133417A1 (en) | 2005-06-07 | 2006-12-14 | Valeant Pharmaceuticals International | Phenylamino isothiazole carboxamidines as mek inhibitors |
| DE102005060466A1 (de) | 2005-12-17 | 2007-06-28 | Bayer Cropscience Ag | Carboxamide |
| ES2540561T3 (es) * | 2005-12-20 | 2015-07-10 | Incyte Corporation | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa |
| US20070203140A1 (en) * | 2006-02-09 | 2007-08-30 | Combs Andrew P | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase |
| JP4297449B2 (ja) | 2006-05-12 | 2009-07-15 | 株式会社サクラクレパス | 墨汁 |
| US20080119491A1 (en) * | 2006-09-19 | 2008-05-22 | Incyte Corporation | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| CL2007002650A1 (es) | 2006-09-19 | 2008-02-08 | Incyte Corp | Compuestos derivados de heterociclo n-hidroxiamino; composicion farmaceutica, util para tratar cancer, infecciones virales y desordenes neurodegenerativos entre otras. |
| WO2008036642A2 (en) | 2006-09-19 | 2008-03-27 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| US20080146624A1 (en) * | 2006-09-19 | 2008-06-19 | Incyte Corporation | Amidines as modulators of indoleamine 2,3-dioxygenase |
| US20080182882A1 (en) * | 2006-11-08 | 2008-07-31 | Incyte Corporation | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase |
| WO2008073825A1 (en) | 2006-12-08 | 2008-06-19 | Exelixis, Inc. | Lxr and fxr modulators |
| TW200845991A (en) * | 2007-01-12 | 2008-12-01 | Smithkline Beecham Corp | N-substituted glycine derivatives: hydroxylase inhibitors |
| US8642660B2 (en) * | 2007-12-21 | 2014-02-04 | The University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| DK2315756T5 (en) | 2008-07-08 | 2015-08-03 | Incyte Corp | 1,2,5-oxadiazoles as inhibitors of indoleamine-2,3-dioxygenase |
-
2007
- 2007-09-18 WO PCT/US2007/078745 patent/WO2008036642A2/en not_active Ceased
- 2007-09-18 CA CA2663057A patent/CA2663057C/en active Active
- 2007-09-18 ES ES07814905.1T patent/ES2444574T3/es active Active
- 2007-09-18 JP JP2009529341A patent/JP5319532B2/ja active Active
- 2007-09-18 EP EP07814905.1A patent/EP2064207B1/en active Active
- 2007-09-18 US US11/856,967 patent/US20080125470A1/en not_active Abandoned
-
2011
- 2011-03-23 US US13/070,069 patent/US8377976B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008036642A2 (en) | 2008-03-27 |
| US20110172279A1 (en) | 2011-07-14 |
| EP2064207A2 (en) | 2009-06-03 |
| JP5319532B2 (ja) | 2013-10-16 |
| US8377976B2 (en) | 2013-02-19 |
| JP2010504346A (ja) | 2010-02-12 |
| CA2663057A1 (en) | 2008-03-27 |
| EP2064207B1 (en) | 2013-11-06 |
| US20080125470A1 (en) | 2008-05-29 |
| CA2663057C (en) | 2015-12-08 |
| WO2008036642A3 (en) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2444574T3 (es) | N-hidroxiamidinoheterociclos como moduladores de la indolamina 2,3-dioxigenasa | |
| ES2704641T3 (es) | Compuestos N-hidroxiamidinoheterocíclicos como moduladores de la indoleamina 2,3-dioxigenasa | |
| ES2540561T3 (es) | N-hidroxiamidinoheterociclos como moduladores de indolamina 2,3-dioxigenasa | |
| ES2799582T3 (es) | Proceso para la síntesis de un inhibidor de indoleamina 2,3-dioxigenasa | |
| JP4990270B2 (ja) | インドールアミン２，３−ジオキシゲナーゼのモジュレーターおよびそれを用いる方法 | |
| US20080119491A1 (en) | Amidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
| US20080146624A1 (en) | Amidines as modulators of indoleamine 2,3-dioxygenase | |
| US20080182882A1 (en) | N-hydroxyamidinoheterocycles as modulators of indoleamine 2,3-dioxygenase | |
| US20070203140A1 (en) | N-hydroxyguanidines as modulators of indoleamine 2,3-dioxygenase | |
| ES2524266T9 (es) | 1,2,5-Oxadiazoles como inhibidores de la indoleamina 2,3-dioxigenasa |